CODING & BILLING
NATIONAL DRUG CODE (NDC) AND BILLING AND DIAGNOSIS CODES FOR KEYTRUDA QLEX
The following codes may be relevant when billing for KEYTRUDA QLEX. It is provided as reference only and may be relevant when billing for KEYTRUDA QLEX, and the administration of this product. This information is current as of February 2026. The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Information about HCPCS codes is based on guidance issued by the CMS applicable to Medicare Part B and may not apply to other public or private payers. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. This information is subject to change. Merck cautions that payer-coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor as to payer-specific requirements.
You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Diagnosis codes should be selected only by a health care professional. Merck and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.
NDC and Packaging Information
The NDC is typically required when submitting a claim with a miscellaneous HCPCS code. Please consult with the payer to understand specific billing requirements.
| PRODUCT | ||
|---|---|---|
| KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) Injection | ||
| PACKAGE | 10-Digit NDC | 11-Digit NDC |
| One carton containing 395 mg pembrolizumab and 4,800 units berahyaluronidase alfa per 2.4 mL (165 mg and 2,000 units per mL), single-dose vial | 0006-3083-01 | 00006-3083-01 |
| One carton containing 790 mg pembrolizumab and 9,600 units berahyaluronidase alfa per 4.8 mL (165 mg and 2,000 units per mL), single-dose vial | 0006-5083-01 | 00006-5083-01 |
| PRODUCT | ||
|---|---|---|
| KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) Injection | ||
| PACKAGE | ||
| One carton containing 395 mg pembrolizumab and 4,800 units berahyaluronidase alfa per 2.4 mL (165 mg and 2,000 units per mL), single-dose vial | ||
| 10-Digit NDC | 11-Digit NDC | |
| 0006-3083-01 | 00006-5083-01 | |
| PACKAGE | ||
| One carton containing 790 mg pembrolizumab and 9,600 units berahyaluronidase alfa per 4.8 mL (165 mg and 2,000 units per mL), single-dose vial | ||
| 10-Digit NDC | 11-Digit NDC | |
| 0006-3083-01 | 00006-5083-01 | |
HCPCS=Healthcare Common Procedure Coding System; CMS=Centers for Medicare & Medicaid Services.
Billing Codes
Below is a list of possible codes that could be relevant for KEYTRUDA QLEX and its administration. Please consult with the applicable payer to understand the payer’s specific billing requirements.
Use the JZ modifier when the entire contents of a single-dose vial are administered to the patient with no drug wasted. It ensures accurate Medicare billing by confirming that no portion of the drug was discarded.
| HCPCS Code2 | |
|---|---|
| HCPCS CODE | DESCRIPTOR |
| J9277 | Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph |
| Revenue Code—for Use in the Hospital Setting3 | |
| REVENUE CODE | DESCRIPTOR |
| 0636 | Drug requiring detailed coding |
| Current Procedural Terminology (CPT®)a Code for Administration4 | |
| CPT CODE | DESCRIPTOR |
| 96401 | Injection and intravenous infusion chemotherapy and other highly complex drug or highly complex biologic agent administration |
aCPT Copyright 2025 American Medical Association. All rights reserved.